Format

Send to

Choose Destination
Blood. 2017 Jun 15;129(24):3175-3183. doi: 10.1182/blood-2016-11-750174. Epub 2017 May 3.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Author information

1
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
2
Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
3
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
4
Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
5
Gabrail Cancer Institute, Canton, OH.
6
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
7
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
8
Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
9
Division of Hematology, University of Calgary, Calgary, AB, Canada.
10
Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY.
11
Blood Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN.
12
Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO.
13
Karyopharm Therapeutics, Inc., Newton, MA; and.
14
Department of Hematology, John Theurer Cancer Center, Hackensack, NJ.

Abstract

Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled. In the dose-escalation phase, patients received 3 to 80 mg/m2 of selinexor in 3- or 4-week cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity. In the dose-expansion phase, patients were treated with selinexor at 35 or 60 mg/m2 The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%). Tumor biopsies showed decreases in cell-signaling pathways (Bcl-2, Bcl-6, c-Myc), reduced proliferation (Ki67), nuclear localization of XPO1 cargos (p53, PTEN), and increased apoptosis after treatment. Twenty-two (31%) of the 70 evaluable patients had an objective responses, including 4 complete responses and 18 partial responses, which were observed across a spectrum of NHL subtypes. A dose of 35 mg/m2 (60 mg) was identified as the RP2D. These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg/m2 is a safe therapy with encouraging and durable anticancer activity in patients with R/R NHL. The trial was registered at www.clinicaltrials.gov as #NCT01607892.

PMID:
28468797
DOI:
10.1182/blood-2016-11-750174
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center